ASEAN has become an imtportant fulcrum in the global pharmaceutical production supply chain

Asia-based BioDlink, a full-service Contract Development and Manufacturing Organisation (CDMO) specialising in biologics and antibody-drug conjugates (ADCs), has built a strong track record over the past decade, offering integrated solutions from early-stage R&D to commercial manufacturing.

- Ayesha Siddiqui

Dr Jun Liu, CEO and Executive Director, BioDlink

With globally compliant quality systems and high-potency Occupational Exposure Bands (OEB)-5 facilities, the company has supported over 100 projects and passed nearly as many GMP audits, including a zero-defect European Union, Qualified Person (QP) inspection. Recently, BioDlink strengthened its global compliance credentials with GMP certifications from Argentina and Brazil. Dr Jun Liu, CEO and Executive Director, BioDlink shares insights into the company’s capacity expansion plans, the role of continuous manufacturing in its long-term strategy, and key trends shaping the CDMO landscape, etc. Edited excerpts:

What are your plans for capacity expansion in biologics and ADC manufacturing?

We are already among the largest biologics CDMO providers within China, and our capacity infrastructure reflects this leadership. Currently, we operate with a combined bioreactor capacity of 20,000 litres for antibody drug substance, with two independent production centres for antibody stock solutions and another three for ADCs, delivering more than 100 clinical projects worldwide, including European and the U.S., in the past three years.